New cancer drug CTX-10726 enters first human tests
NCT ID NCT07419841
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called CTX-10726 in about 70 people with advanced gastroesophageal, liver, endometrial, or kidney cancers that have stopped responding to standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug by IV every two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTX-10726 (an experimental drug given by IV infusion every two weeks)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 70 participants, so the drug may not prove safe or effective. Side effects are unknown and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Prisma Health Cancer Institute
RECRUITINGGreenville, South Carolina, 29605, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
START New York
RECRUITINGLake Success, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact